December 28, 2018 08:18 AM ESTUpdated 08:51 AM
Financing

Backed by a pi­o­neer in BiTE tech, Har­poon marks a course for an IPO and an ear­ly dis­play of po­ten­tial

John Carroll

Editor & Founder

Can a next-gen BiTE de­vised by a pi­o­neer in the field at­tract in­vestors in­to an on­col­o­gy IPO based al­most en­tire­ly on mouse da­ta? Har­poon Ther­a­peu­tics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

Sen­ate Ju­di­cia­ry Com­mit­tee ad­vances patent bill with new pro­tec­tions for phar­ma chal­lenges

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

A service from the Financial Times